80 related articles for article (PubMed ID: 16268667)
1. Rotigotine: in Parkinson's disease.
Reynolds NA; Wellington K; Easthope SE
CNS Drugs; 2005; 19(11):973-81. PubMed ID: 16268667
[TBL] [Abstract][Full Text] [Related]
2. Transdermal Rotigotine at End-of-Life for Parkinson's Disease: Association With Measures of Distress.
Hewer C; Richfield E; Halton C; Alty J
J Pain Symptom Manage; 2024 Feb; 67(2):e121-e128. PubMed ID: 37838081
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of rotigotine extended-release microspheres for intramuscular injection in patients with early-stage Parkinson's disease.
Sun H; Dong C; Wu M; Li X; Song H; Zhang Y; Liu C; Liu P; Liu W; Chan P
Br J Clin Pharmacol; 2024 Apr; 90(4):1094-1102. PubMed ID: 38148659
[TBL] [Abstract][Full Text] [Related]
4. The Smart Drug Delivery of Rotigotine Using Transdermal Patch for the Successful Management of Parkinson's Disease.
Dharmian JP; PushpaNathan ACS; Ramakrishnan P; Subramanian RN; Levy JD; Palani P; Krishnaswami V
Cent Nerv Syst Agents Med Chem; 2024 Jun; ():. PubMed ID: 38910418
[TBL] [Abstract][Full Text] [Related]
5. Parkinson's disease: symptoms and medications at the end of life.
Wilson EA; King-Oakley E; Richfield EW
BMJ Support Palliat Care; 2024 Jan; 13(e3):e912-e915. PubMed ID: 37463763
[TBL] [Abstract][Full Text] [Related]
6. 20-Week intramuscular toxicity study of rotigotine behenate extended-release microspheres for injection via intramuscular injection in cynomolgus monkeys.
Zhao X; Guo C; Zhang H; Yu X; Zhu X; Du G; Tian J; Liu W; Song T; Chen X; Guo W
Food Chem Toxicol; 2024 Jun; 190():114786. PubMed ID: 38849048
[TBL] [Abstract][Full Text] [Related]
7. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease.
Sanford M; Scott LJ
CNS Drugs; 2011 Aug; 25(8):699-719. PubMed ID: 21790211
[TBL] [Abstract][Full Text] [Related]
8. Identifying potential drug-target interactions based on ensemble deep learning.
Zhou L; Wang Y; Peng L; Li Z; Luo X
Front Aging Neurosci; 2023; 15():1176400. PubMed ID: 37396659
[TBL] [Abstract][Full Text] [Related]
9. Structural genomics of the human dopamine receptor system.
Xu P; Huang S; Krumm BE; Zhuang Y; Mao C; Zhang Y; Wang Y; Huang XP; Liu YF; He X; Li H; Yin W; Jiang Y; Zhang Y; Roth BL; Xu HE
Cell Res; 2023 Aug; 33(8):604-616. PubMed ID: 37221270
[TBL] [Abstract][Full Text] [Related]
10. Identifying Dopamine D3 Receptor Ligands through Virtual Screening and Exploring the Binding Modes of Hit Compounds.
Jin H; Wu C; Su R; Sun T; Li X; Guo C
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677583
[TBL] [Abstract][Full Text] [Related]
11. Integrated Transcriptome and Untargeted Metabolomic Analyses Revealed the Role of Methyltransferase Lae1 in the Regulation of Phospholipid Metabolism in
Shen Y; Zhang Y; Zhang H; Wang X; Chen J; Li Y
J Fungi (Basel); 2023 Jan; 9(1):. PubMed ID: 36675941
[TBL] [Abstract][Full Text] [Related]
12. Importance of Nanoparticles for the Delivery of Antiparkinsonian Drugs.
Silva S; Almeida AJ; Vale N
Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33917696
[TBL] [Abstract][Full Text] [Related]
13. Dopamine receptors in emesis: Molecular mechanisms and potential therapeutic function.
Belkacemi L; Darmani NA
Pharmacol Res; 2020 Nov; 161():105124. PubMed ID: 32814171
[TBL] [Abstract][Full Text] [Related]
14. Rotigotine Effects on Bladder Function in Patients with Parkinson's Disease.
Brusa L; Petta F; Farullo G; Iacovelli V; Ponzo V; Iani C; Stanzione P; Agró EF
Mov Disord Clin Pract; 2017; 4(4):586-589. PubMed ID: 30363351
[TBL] [Abstract][Full Text] [Related]
15. Rotigotine in the treatment of primary restless legs syndrome: A meta-analysis of randomized placebo-controlled trials.
Ding J; Fan W; Chen HH; Yan P; Sun SG; Zheng J
J Huazhong Univ Sci Technolog Med Sci; 2015 Apr; 35(2):169-175. PubMed ID: 25877347
[TBL] [Abstract][Full Text] [Related]
16. Transdermal Rotigotine Improves Sleep Fragmentation in Parkinson's Disease: Results of the Multicenter, Prospective SLEEP-FRAM Study.
Pagonabarraga J; Piñol G; Cardozo A; Sanz P; Puente V; Otermín P; Legarda I; Delgado T; Serrano C; Balaguer E; Aguirregomozcorta M; Álvarez R; Kulisevsky JJ
Parkinsons Dis; 2015; 2015():131508. PubMed ID: 25793143
[TBL] [Abstract][Full Text] [Related]
17. Homology modeling of dopamine D2 and D3 receptors: molecular dynamics refinement and docking evaluation.
Platania CB; Salomone S; Leggio GM; Drago F; Bucolo C
PLoS One; 2012; 7(9):e44316. PubMed ID: 22970199
[TBL] [Abstract][Full Text] [Related]
18. Influence of transdermal rotigotine on ovulation suppression by a combined oral contraceptive.
Braun M; Elshoff JP; Andreas JO; Müller LI; Horstmann R
Br J Clin Pharmacol; 2009 Sep; 68(3):386-94. PubMed ID: 19740396
[TBL] [Abstract][Full Text] [Related]
19. Rotigotine transdermal system: a short review.
Bunten S; Happe S
Neuropsychiatr Dis Treat; 2006 Dec; 2(4):421-6. PubMed ID: 19412491
[TBL] [Abstract][Full Text] [Related]
20. Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine.
Braun M; Cawello W; Boekens H; Horstmann R
Br J Clin Pharmacol; 2009 Feb; 67(2):209-15. PubMed ID: 19094160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
